Treats Moderate. ANDA 78324, held by Breckenridge Pharm. Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 78324 (Estradiol And Norethindrone Acetate), held by Breckenridge Pharm, was first approved by FDA on Apr 17, 2008, with 5 approved supplements and 0 published complete response letters.
Estradiol/Norethindrone Acetate Tablets are indicated for: Estradiol/Norethindrone Acetate Tablets are an estrogen and progestin combination indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitations of Use: When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2008 | Original application | Approved | None posted |
| Estradiol And Norethindrone Acetate1MG;0.5MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| Estradiol And Norethindrone Acetate0.5MG;0.1MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| Apr 21, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 21, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 21, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 21, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 9, 2011 | Supplement 2Manufacturing | Approved | None posted |
| Apr 17, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters